Oncotarget


2024 Press Releases

BRCA1 and BRCA2 in a Cohort of Ovarian Cancer Patients From the Salento Peninsula


FOR IMMEDIATE RELEASE
2024-02-28

“Ovarian cancer (OC) is the third most prevalent type of gynecologic cancer affecting women after cervical and uterine cancer [1]. It is also considered the most fatal of all gynecological cancers [...]”


 

BUFFALO, NY- February 28, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.”... continue reading >>

GZ17-6.02 With Bexarotene Kills Mycosis Fungoides Cells


FOR IMMEDIATE RELEASE
2024-02-26

“The present studies were performed to extend our knowledge of GZ17-6.02 biology from that known in solid tumor cell types such as prostate cancer cells to liquid tumor cell types, for example, mycosis fungoides.”


 

BUFFALO, NY- February 26, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 8, 2024, entitled, “GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.”

 

In this new study, researchers Michael R. Booth, Laurence Booth, Jane L. Roberts,... continue reading >>

Combining Causal and Correlative Approaches to Discover Response Biomarkers to Paclitaxel


FOR IMMEDIATE RELEASE
2024-02-21

“The discovery of predictive biomarkers to paclitaxel vulnerability [such] as SSR3 [signal sequence receptor 3] promises to significantly impact cancer treatment.”


 

BUFFALO, NY- February 21, 2024 – A new research perspective was published in Oncotarget's Volume 15 on February 8, 2024, entitled, “Combining causal and correlative approaches to discover biomarkers of response to paclitaxel.”

 

As discussed in this new paper, researchers Alberto Moscona-Nissan, Karl J. Habashy, Victor A. Arrieta,... continue reading >>

NTRK Gene Fusion in Papillary Thyroid Cancer: A Clinicogenomic Biobank and Record Linkage Study From Finland


FOR IMMEDIATE RELEASE
2024-02-19

“Estimates of the frequency of NTRK gene fusion in large cohorts of patients with solid tumors come from a limited number of studies. [...]. We aimed to address this gap by evaluating patients with papillary thyroid cancer (PTC) from Finland [...]”


 

BUFFALO, NY- February 19, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage ... continue reading >>

Genetic and Therapeutic Landscapes in Cohort of Pancreatic Adenocarcinomas Using NGS and Machine Learning


FOR IMMEDIATE RELEASE
2024-02-14

“Our study was designed to build specific mutational and therapeutic landscapes of pancreatic cancer among the Russian population.”


 

BUFFALO, NY- February 14, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis.”

 

About 7% of all cancer deaths are caused by pancreatic cancer (PCa). PCa is known ... continue reading >>

Differential Expression of Mad2 Gene in Human Esophageal Cancer


FOR IMMEDIATE RELEASE
2024-02-12

“[...] people of the northeastern region [of India] consume betel quid, consisting of raw areca nut [...]. People often swallow the entire betel-quid after chewing, which is believed to contribute to the development of oral, esophageal, and gastric cancers.”


 

BUFFALO, NY- February 12, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational... continue reading >>

Evaluation of Ruxolitinib, a Janus Kinase Inhibitor, in Multiple Myeloma


FOR IMMEDIATE RELEASE
2024-02-07

“[...] the results of the studies presented in this review will hopefully provide the impetus for conducting additional preclinical and clinical studies to evaluate RUX in the setting of MM as well as other types of cancer.”


 

BUFFALO, NY- February 7, 2024 – A new research perspective was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”

 

In this new paper, researchers Ashley... continue reading >>

Drug Discovery in Academia; Dumping in the Publication Landfill?


FOR IMMEDIATE RELEASE
2024-02-05

“[...] fruitful efforts to bring more drugs from bench to bedside could only be possible if we do not leave them ‘midway’!”


 

BUFFALO, NY- February 5, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “The fate of drug discovery in academia; dumping in the publication landfill?

 

In this new editorial, researchers Uzma Saqib, Isaac S. Demaree, Alexander G. Obukhov, Mirza S. Baig, Amiram Ariel, and Krishnan Hajela, from Devi Ahilya... continue reading >>

BCAS1 Defines a Heterogeneous Cell Population in Diffuse Glioma Patients


FOR IMMEDIATE RELEASE
2024-01-31

“[...] this is the first study describing a BCAS1+ cell population in a large cohort of diffuse glioma patients.”


 

BUFFALO, NY- January 31, 2024 – A new research paper was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “BCAS1 defines a heterogeneous cell population in diffuse gliomas.”

 

Oligodendrocyte precursor markers have become of great interest to identify new diagnostic and therapeutic targets for diffuse gliomas, since state-of-the-art studies point towards immature ... continue reading >>

Genetic Alterations in Thyroid Cancer Mediate Resistance to BRAF Inhibition and Anaplastic Transformation


FOR IMMEDIATE RELEASE
2024-01-29

“An improved understanding of the molecular basis of thyroid cancer has led to the development of new targeted agents.”


 

BUFFALO, NY- January 29, 2024 – A new research perspective was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.”

 

In this new paper, researchers Mark Lee and Luc GT Morris from New York Presbyterian Hospital and Memorial Sloan Kettering Cancer ... continue reading >>

Case Report: Lazarus Effect in a Patient Treated With Osimertinib for NSCLC With Leptomeningeal Disease


FOR IMMEDIATE RELEASE
2024-01-24

“[...] this case supports a body of literature noting potentially dramatic clinical benefits of administering appropriate oncogene directed targeted therapy [...]”


 

BUFFALO, NY- January 24, 2024 – A new case report was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report.”

 

Osimertinib has been shown to be... continue reading >>

Bone Marrow Adipocytes Provide Early Sign of Progression From MGUS to Multiple Myeloma


FOR IMMEDIATE RELEASE
2024-01-22

“[...] bone marrow adipocyte density, size, and roundness are significantly different between [MGUS and MM] and could provide early signs for progression [...] to MM.”


 

BUFFALO, NY- January 22, 2024 – A new research perspective was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.”

 

Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal... continue reading >>

ATR Inhibition Using Gartisertib in Patient-derived Glioblastoma Cell Lines


FOR IMMEDIATE RELEASE
2024-01-17

“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.”


 

BUFFALO, NY- January 17, 2024 – A new research paper was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.”

 

Glioblastoma cells can restrict the DNA-damaging effects of temozolomide (TMZ) and radiation therapy (RT) using the... continue reading >>

Reductive Carboxylation of Glutamine as a Potential Target in AML


FOR IMMEDIATE RELEASE
2024-01-16

“Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.”


 

BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 1, 2023, entitled, “Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia.”

 

In this new editorial, researchers Alessia Roma, Lawrence D. Goodridge and Paul A. Spagnuolo from the University of Guelph discuss acute myeloid leukemia (AML) — an aggressive cancer of... continue reading >>

Toward Treating PARP Inhibitor-resistant Ovarian Cancers


FOR IMMEDIATE RELEASE
2024-01-10

“This initiative is geared towards identifying additional biomarkers that can aid in selecting the most appropriate treatments for ovarian cancer.”


 

BUFFALO, NY- January 10, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 22, 2023, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.”

 

Over 80% of ovarian cancer cases experience recurrence, resulting in roughly 12,000 annual deaths in the United States. While targeted... continue reading >>

Transformation-associated Recombination (TAR) Cloning and Its Applications


FOR IMMEDIATE RELEASE
2024-01-08

“TAR cloning is used to genetically engineer synthetic viruses with novel properties that may be used for the development of new vaccines.”


BUFFALO, NY- January 8, 2024 – A new review paper was published in Oncotarget's Volume 14 on December 22, 2023, entitled, “Transformation-associated recombination (TAR) cloning and its applications for gene function; genome architecture and evolution; biotechnology and biomedicine.”

Transformation-associated recombination (TAR) cloning represents a unique... continue reading >>

Harnessing Cancer Stem Cell-derived Exosomes


FOR IMMEDIATE RELEASE
2024-01-03

“[...] recent significant advances in understanding [...] CSC-Exos have revealed numerous potential applications for diagnosis and treatment.”


 

BUFFALO, NY- January 3, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, “Therapeutically harnessing cancer stem cell-derived exosomes.”

 

In this editorial, researcher Yong Teng from Emory University discusses cancer stem cell-derived exosomes. Cancer stem cells (CSCs), a small population of cancer... continue reading >>



Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC